Literature DB >> 15727389

Lipoprotein (A) levels in type 2 diabetic patients with diabetic retinopathy.

U G O Ergün1, S Oztüzün, G Seydaoglu.   

Abstract

To examine a possible association between lipoprotein(a) [Lp(a)] levels and diabetic retinopathy in patients with type 2 diabetes mellitus. 100 type 2 diabetic patients were assessed with the following parameters: age, body mass index, duration of diabetes, blood pressure, fasting plasma glucose, total cholesterol, HDL-cholesterol, triglycerides, blood urea nitrogen, creatinine, Lp(a), and albumin excretion rate (AER). Retinopathy was classified as normal retina (NR), non-proliferative diabetic retinopathy (NPDR), and proliferative diabetic retinopathy (PDR) by an ophthalmologist. The PDR group had higher cholesterol (t=-2.24, p<0.05) and creatinine (z=-2.547, p<0.05) levels than the NPDR group. The PDR group had a higher value of AER (z=-2.439, p<0.01) than the NR group. The possibility of developing diabetic retinopathy after 10 years of diabetes was found to be 6.5 fold high (OR; 6.57, 95% CI 1.74-24.79; p<0.05). The Lp(a) levels were similar in the patients with retinopathy and those without retinopathy. In the study, there was no evidence for a relationship between the serum Lp(a) levels and diabetic retinopathy in type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15727389

Source DB:  PubMed          Journal:  Med J Malaysia        ISSN: 0300-5283


  2 in total

1.  Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications.

Authors:  Radhakrishnan Chandni; Kollengode Parameswaran Ramamoorthy
Journal:  World J Diabetes       Date:  2012-05-15

2.  Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus.

Authors:  Sunny S Singh; Mardin Rashid; Aloysius G Lieverse; Florian Kronenberg; Claudia Lamina; Monique T Mulder; Yolanda B de Rijke; Eric J G Sijbrands; Mandy van Hoek
Journal:  Diabetologia       Date:  2020-03-09       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.